Drugs / AB-836
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04775797 | Jun 2021 → Nov 2022 | chronic hepatitis B virus infection | Arbutus Biopharma Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-836 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04775797 ↗ |
| Action | Inhibit | “AB-836, an HBV Capsid Inhibitor” NCT04775797 ↗ |
| Modality | Small molecule | — CHEMBL5314907 ↗ |